BBP News and Press, Virtus LifeSci Biotech Products From 04/21/21

This has been a long, long boom in the amount of money that's flowed into this sector, and I don't think I've ever seen anything like it in my own career. This has been VC money going into early-stage startups, it's been IPOs, it's been follow-on financing of already public companies....

Since U.S. Treasury bonds have fallen more than -20% in value, it looks like we might've seen a short-term bottom and an opportunity to profit in the bond market. Which sectors are performing well in the intermediate term, as well as those that are taking a breather in the short term....

One of my many favorite tools to use when analyzing the markets is a Relative Rotation Graph (or “RRG”). I’m going to focus on using RRG to explain what’s happening under the surface in the market today. You can put any benchmark in the middle, at the z...

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of thi...

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those ...

In our opinion, telehealth will remain the leading segment of the internet healthcare market as the market shifts away from in-person medical visits. According to Apple CEO Tim Cook, “I believe, if you zoom out into the future, and you look back, and you ask the question, ...

Risk assets continued their historic run last week with EM equities and commodities leading the way. Bonds sold off as the 10-year Treasury note yield broke above 1.20% for the first time since the lows last spring. The 10-year TIPS yield closed the week at 1.02%, near the all-tim...

After a dramatic year of volatility, the U.S. stock market ended 2020 at record highs. Can this momentum continue this year? ESG investments clearly outperformed in 2020. 2021 should be a year of much better cash flow for companies. For further details see: A Stock Picke...

The Healthcare sector ranks seventh in Q1'21. Based on an aggregation of ratings of the 354 stocks in the Healthcare sector. IXJ is our top-rated Healthcare sector ETF and SHSKX is our top-rated Healthcare sector mutual fund. For further details see: Best And Worst Q1 20...

2020 was a busy year for global healthcare with unprecedented efforts to develop vaccines, treatments, and diagnostics for COVID-19. Deal flow in the sector continued to gain momentum in 2020, with M&A transactions and product licensing deals totalling five-year highs as large-cap...